International Journal of Medical Laboratory

en مقایسه سطح سرمی گلوتامات دهیدروژناز، گلوتامین سنتتاز و آسپاراژین سنتتاز در بیماران مبتلا به اختلال افسردگی اساسی قبل و بعد از درمان با کتامین Evaluating the Effects of Ketamine on Serum Glutamate Dehydrogenase, Glutamine Synthetase and Asparagine Synthetase Levels in Patients with Major Depressive Disorder Before and After Ketamine Treatment بیوشیمی Biochemistry پژوهشي Research <div style="text-align: justify;">Introduction: It has been revealed that major depressive disorder (MDD)is a common and debilitating psychiatric disorder. Dysfunctional enzymes involved in neurotransmission glutamate dehydrogenase (GDH), Glutamine synthetase (GS) and Asparagine synthetase (ASNS) may underlie the pathophysiology of MDD. The present project aimed to explore the effects of Ketamine on GDH, GS and ASNS in MDD patients. This study provides evidence of interactions between ketamine and GDH, ASNS and GS levels in patients with MDD. Materials and Methods: Patients with MDD are referred to the psychiatric ward of Shaheed Yahyanejad Hospital for regular follow-up. Patients diagnosed with MDD were based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), structured clinical interviews, as well as the severity of depression based on clinical criteria determined by a specialist physician. Serum samples from MDD patients before and after ketamine administration were taken to examine the changes in GDH, ASNS and GS levels. In this project, 29 patients with MDD therapy were evaluated with ketamine (0.75 mg/kg). Results: Our study showed that after administrating ketamine, the level of ASNS and Glutamate dehydrogenase GDH in patients with MDD was reduced compared to pre-treatment. However, the level of GS was increased compared to before treatment. The results show that ketamine occurs at the metabolism level in MDD patients. Also, our results demonstrated that GDH, ASNS, and GS levels can be measured to evaluate the effect of Ketamine on MDD patients. Conclusions: Patient success has improved depression after two months of administrating ketamine. Marginally, more than 80% of patients diagnosed with MDD treated with ketamine showed complete remission. Current results may be helpful in understanding the mechanisms responsible for ketamine’s clinical efficacy.</div> Major Depressive Disorder (MDD), ketamine, ketamine treatment Ketamine, Ketamine treatment, Major depressive disorder 86 92 http://ijml.ssu.ac.ir/browse.php?a_code=A-10-350-4&slc_lang=en&sid=1 Eisa Taheri Tary عیسی طاهری تاری eesataheri98@gmail.com No 1 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 2 Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran . Department of Psychiatry, School of Medicine, Yahyanejad Hospital Babol University of Medical Sciences, Babol, Iran 1 Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 2 Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran . Department of Psychiatry, School of Medicine, Yahyanejad Hospital Babol University of Medical Sciences, Babol, Iran Durdi Qujeq دردی قوجق dqujeq@gmail.com https://orcid.org/0000-0003-1344-9344 Yes Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 2 Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 2 Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran Farzan Kheirkhah فرزان خیر خواه drfarzan@yahoo.com 0000-0003-1420-5480 No Environmental Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Environmental Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Karimollah Hajian-tilaki کریم اله حاجیان تیلکی drhajian@yahoo.com 0000-0001-6830-1916 No Environmental Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Environmental Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran. Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran